Sodium-Glucose Transporter 2 Inhibitors
- Name
- Sodium-Glucose Transporter 2 Inhibitors
- Accession Number
- DBCAT004076
- Description
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney, and are used in the treatment of TYPE 2 DIABETES MELLITUS.
- Drugs
Drug Drug Description Dapagliflozin A sodium-glucose cotransporter 2 inhibitor used in the management of type 2 diabetes mellitus. Empagliflozin An SGLT2 inhibitor used to manage type 2 diabetes mellitus. Ipragliflozin Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2. Tofogliflozin Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2. Ertugliflozin An SGLT2 inhibitor used to treat type 2 diabetes mellitus alone or in combination with other antidiabetic drugs. Sotagliflozin An orally administered dual SGLT1/2 inhibitor used alongside insulin to improve glycemic control in patients with type 1 diabetes mellitus. Remogliflozin etabonate Remogliflozin etabonate has been used in trials studying the treatment and basic science of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2. Licogliflozin Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity). Bexagliflozin A sodium-glucose co-transporter 2 inhibitor used to improve glycemic control in patients with type 2 diabetes mellitus. - Drugs & Drug Targets